AERMONY RESPICLICK POWDER (METERED DOSE)

País: Canadà

Idioma: anglès

Font: Health Canada

Compra'l ara

Descargar Fitxa tècnica (SPC)
14-12-2018

ingredients actius:

FLUTICASONE PROPIONATE

Disponible des:

TEVA CANADA LIMITED

Codi ATC:

R03BA05

Designació comuna internacional (DCI):

FLUTICASONE

Dosis:

113MCG

formulario farmacéutico:

POWDER (METERED DOSE)

Composición:

FLUTICASONE PROPIONATE 113MCG

Vía de administración:

INHALATION

Unidades en paquete:

60 DOSES

tipo de receta:

Prescription

Área terapéutica:

ADRENALS

Resumen del producto:

Active ingredient group (AIG) number: 0124685012; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2017-08-22

Fitxa tècnica

                                _Aermony RESPICLICK Product Monograph _
_Page 1 of 45_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
Aermony RESPICLICK
TM
fluticasone propionate inhalation powder, Mfr. Std.
55 mcg, 113 mcg and 232 mcg fluticasone propionate / actuation
Corticosteroid for Oral Inhalation
Distributed by:
Teva Canada Limited
Toronto, Ontario M1B 2K9
Manufactured for:
Teva Canada Innovation
Montréal, Quebec H2Z 1S8
Date of Preparation:
December 14, 2018
Submission Control No: 219965
Aermony RESPICLICK is a trademark of Ivax International B.V., a member
of the Teva Group; used under license.
_ _
_Aermony RESPICLICK Product Monograph _
_Page 2 of 45 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
.................................
                                
                                Llegiu el document complet
                                
                            

Documents en altres idiomes

Fitxa tècnica Fitxa tècnica francès 14-12-2018

Cerqueu alertes relacionades amb aquest producte